WO2001058476A3 - Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity - Google Patents

Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity Download PDF

Info

Publication number
WO2001058476A3
WO2001058476A3 PCT/EP2001/001517 EP0101517W WO0158476A3 WO 2001058476 A3 WO2001058476 A3 WO 2001058476A3 EP 0101517 W EP0101517 W EP 0101517W WO 0158476 A3 WO0158476 A3 WO 0158476A3
Authority
WO
WIPO (PCT)
Prior art keywords
plasmin
activity
methods
disease
alzheimer
Prior art date
Application number
PCT/EP2001/001517
Other languages
French (fr)
Other versions
WO2001058476A2 (en
Inventor
Carlos G Dotti
Maria D Ledesma
Original Assignee
European Molecular Biology Lab Embl
Carlos G Dotti
Maria D Ledesma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by European Molecular Biology Lab Embl, Carlos G Dotti, Maria D Ledesma filed Critical European Molecular Biology Lab Embl
Priority to AU31733/01A priority Critical patent/AU3173301A/en
Publication of WO2001058476A2 publication Critical patent/WO2001058476A2/en
Publication of WO2001058476A3 publication Critical patent/WO2001058476A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Abstract

The present invention relates to methods of treating or preventing Alzheimer's disease in a subject by causing an increase in plasmin or plasmin-like activity in the subject's brain. The present invention further relates to compositions useful for increasing the plasmin or plasmin-like activity in a subject's brain, and to methods of identifying compositions useful for increasing plasmin or plasmin-like activity in a subject's brain. In addition, methods of detecting Alzheimer's disease are provided.
PCT/EP2001/001517 2000-02-11 2001-02-12 Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity WO2001058476A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU31733/01A AU3173301A (en) 2000-02-11 2001-02-12 Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50244800A 2000-02-11 2000-02-11
US09/502,448 2000-02-11
US71492800A 2000-11-17 2000-11-17
US09/714,928 2000-11-17

Publications (2)

Publication Number Publication Date
WO2001058476A2 WO2001058476A2 (en) 2001-08-16
WO2001058476A3 true WO2001058476A3 (en) 2002-03-28

Family

ID=27054164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/001517 WO2001058476A2 (en) 2000-02-11 2001-02-12 Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity

Country Status (2)

Country Link
AU (1) AU3173301A (en)
WO (1) WO2001058476A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199463A1 (en) 2002-04-23 2003-10-23 Silviu Itescu DNA enzyme to inhibit plasminogen activator inhibitor-1
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
EP1558268A4 (en) * 2002-09-17 2008-09-17 Univ New York Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
AU2006267176A1 (en) 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
US8969295B2 (en) 2006-04-14 2015-03-03 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
EP2323687A2 (en) * 2008-09-11 2011-05-25 H. Lundbeck A/S Method of upregulating sorla for the treatment of alzheimer's disease
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
WO2012117076A2 (en) 2011-03-01 2012-09-07 Pharnext Baclofen and acamprosate based therapy of neurogical disorders
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
CN111344004A (en) * 2017-06-19 2020-06-26 泰伦基国际有限公司 Method and medicine for regulating GLP-1/GLP-1R
TW201904990A (en) * 2017-06-23 2019-02-01 美商波麥堤克生物治療股份有限公司 Plasminogen treatment for conditions associated with PAI-1 overexpression
CN115244181A (en) * 2020-03-11 2022-10-25 上海信致医药科技有限公司 Novel use of aspirin compounds to increase nucleic acid expression
US20230346897A1 (en) * 2020-03-24 2023-11-02 Talengen International Limited Method and drug for promoting degradation of misfolded protein and aggregate thereof
WO2021190558A1 (en) * 2020-03-24 2021-09-30 泰伦基国际有限公司 Method and drug for treating alzheimer disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631786A1 (en) * 1993-07-02 1995-01-04 IMMUNO Aktiengesellschaft Lys - plasminogen in the prevention and treatment of ischemia and reperfusian injury
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
DE19641180A1 (en) * 1996-09-24 1998-03-26 Schering Ag A method of displaying APP secretase modulation and its use as an agent for the treatment of Alzheimer's disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631786A1 (en) * 1993-07-02 1995-01-04 IMMUNO Aktiengesellschaft Lys - plasminogen in the prevention and treatment of ischemia and reperfusian injury
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
DE19641180A1 (en) * 1996-09-24 1998-03-26 Schering Ag A method of displaying APP secretase modulation and its use as an agent for the treatment of Alzheimer's disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEYTUS S P ET AL: "A QUANTITATIVE ASSAY FOR THE ACTIVATION OF PLASMINOGEN BY TRANSFORMED CELL IN-SITU AND BY URO KINASE", BIOCHEMISTRY, vol. 20, no. 15, 1981, pages 4307 - 4314, XP002178382, ISSN: 0006-2960 *
REDDY D S: "NEWER THROMBOLYTIC DRUGS FOR ACUTE MYOCARDIAL INFARCTION", INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, XX, XX, vol. 36, no. 1, 1998, pages 1 - 15, XP001010498, ISSN: 0019-5189 *

Also Published As

Publication number Publication date
WO2001058476A2 (en) 2001-08-16
AU3173301A (en) 2001-08-20

Similar Documents

Publication Publication Date Title
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
WO2002088101A3 (en) Inhibitors of bace
AU2001233299A1 (en) Methods for treating alzheimer's disease
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
AU2002306848A1 (en) Methods of treating alzheimer's disease with piperidin derivates
GB0225474D0 (en) Therapeutic agents
WO2001066564A3 (en) Gamma-secretase inhibitors
EP1769791A3 (en) Treatment of Alzheimer's disease with cell cycle inhibitors
SI1594833T1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
AP2004003026A0 (en) Methods for treating ocular neovascular diseases.
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
ATE320803T1 (en) METHOD FOR TREATING ALZHEIMER'S DISEASE
BRPI0316438C1 (en) use of erythropoietin in heart disease
GB0421639D0 (en) Methods and compositions relating to alzheimer's disease
DE60231804D1 (en) USE OF HEPCIDINE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF IRON HOMEOSTASTE DISORDER
GB0225475D0 (en) Therapeutic agents
AU2001273132A1 (en) Compounds to treat alzheimer's disease
WO2003007803A3 (en) Methods for diagnosing and treating alzheimer's disease and parkinson's disease
EA200300027A1 (en) METHOD OF TREATING CARDIOVASCULAR DISEASES
WO2006110588A8 (en) Methods for treating mild cognitive impairment
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
PT1152762E (en) USE OF DEOXYGEGANIN IN THE TREATMENT OF ALZHEIMER'S DEMENTIA

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP